Calix (CALX) director Carl Russo reports grant of 11,663 stock options
Rhea-AI Filing Summary
Calix, Inc. director and 10% owner Carl Russo reported an automatic grant of employee stock options on common stock. The filing shows an award of 11,663 stock options with an exercise price of $53.59 per share, dated January 2, 2026. These options begin to vest with respect to 25% of the underlying shares on each anniversary of the grant date, starting one year after January 2, 2026, and are listed as exercisable from January 2, 2027 until expiration on January 2, 2036. Following this grant, Russo is shown as directly holding 11,663 derivative securities tied to Calix common stock.
Positive
- None.
Negative
- None.
FAQ
What insider transaction did CALX report for Carl Russo?
The report shows that Carl Russo, a director and 10% owner of Calix, Inc., received an automatic grant of 11,663 employee stock options on the company’s common stock.
What is the exercise price of Carl Russo’s Calix (CALX) stock options?
The employee stock options reported for Carl Russo have an exercise price of $53.59 per share for Calix common stock.
How do Carl Russo’s new Calix stock options vest?
According to the disclosure, the automatically awarded option vests and becomes exercisable as to 25% of the shares of common stock underlying the option on each anniversary of the January 2, 2026 grant date.
What are the exercisable and expiration dates of the CALX options granted to Carl Russo?
The filing lists the employee stock options as first exercisable on January 2, 2027 with an expiration date of January 2, 2036.
How many derivative securities does Carl Russo beneficially own after this Calix transaction?
After the reported grant, Carl Russo is shown as beneficially owning 11,663 derivative securities (employee stock options) related to Calix common stock, held directly.
What is SEC Form 4 in the context of Calix (CALX)?
Form 4 is a required SEC filing where Calix insiders, such as directors and 10% owners, report changes in their beneficial ownership of the company’s securities, including new stock option grants.